SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebiuss Q3 results sparked a sharp, volatile reaction: despite a strong reported quarter, traders focused on higher planned capital spending and delayed capacity and revenue milestones, raising concerns about funding needs and potential dilution. Bulls argued that strong AI-cloud demand, customer prepayments and the longer-term outlook supported the business, while some also blamed broader pressure from Nvidia-related headlines.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of Nvidia board discussions about potentially removing Jensen Huang, amid allegations involving a company executive and a suspected Chinese spy, have driven concern about leadership continuity and national-security scrutiny. Traders are divided between fearing a CEO transition and further fallout, and viewing the selloff as a buying opportunity because Nvidias AI business remains strong.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas reported Q3 revenue beat and raised outlook are driving attention, with traders highlighting its large backlog and earlier profitability target. Bulls are calling for a short squeeze, while skeptics point to weaker margins, a wider adjusted EBITDA loss, and falling cash reserves.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines stronger-than-expected Q3 results, including positive free cash flow and a record backlog, are driving attention, with traders also citing the companys revenue outlook. Many see the report as a potential turnaround, while skeptics point to ongoing losses, dilution concerns and the stocks history of giving back gains.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Traders are focused on the FDAs Nov. 22 decision on Capricors deramiocel for Duchenne muscular dystrophy, with the application now centered on preserving upper-limb function. The recent rally has fueled approval and short-squeeze speculation, while skeptics point to the earlier advisory committee vote and warn that the outcome remains uncertain.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

A strong quarterly report and raised outlook sparked a sharp rally, but traders then focused on reports of turmoil around Nvidia CEO Jensen Huang and whether it could affect CoreWeaves ties to Nvidia. Bulls say AI demand and contracted backlog remain intact, while bears point to heavy debt costs and potential dilution as risks that the earnings momentum may not resolve.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

BRUN is drawing attention after Q3 results showed sharply higher year-over-year revenue but missed analyst expectations. Traders are split between optimism about its AI-cloud backlog and project financing and concern that contracts have yet to translate into sustained revenue and profitability.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs confirmed decision to remove Strategy from its indexes is driving concern about passive-fund selling and weaker institutional demand; traders also point to Bitcoins decline as pressure on the stock. Bearish voices expect further downside, while bulls argue the index news is priced in and Bitcoins direction matters more.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

ERocks quarterly results are drawing attention, with traders highlighting a return to profitability, strong revenue growth, and reaffirmed full-year guidance alongside a larger backlog tied to AI data-center power demand. Many see the report as bullish and speculate that high short interest could amplify a move, while others remain cautious about execution and volatile price action.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedixs quarterly results drew attention, but managements decision to defer 2027 DefenCath revenue guidance amid uncertainty around CMS reimbursement, utilization and Medicare Advantage is the central concern. Traders are weighing that unclear outlook against stronger-than-expected results and the Heron acquisitions potential to diversify revenue, with reactions split between optimism about the broader portfolio and concern about DefenCaths reimbursement outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High?

The consensus price target hints at a 120.2% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of +15.79% and -39.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2026 and provided business highlights...

Prothena to Report Third Quarter 2026 Financial Results on November 5

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2026 financial results on Thursday...

Prothena's Partnership Strategy: Growth Driver or Limitation?

PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key challenges.

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

CRMD vs. PRTA: Which Stock Is the Better Value Option?

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright...

KMDA or PRTA: Which Is the Better Value Stock Right Now?

KMDA vs. PRTA: Which Stock Is the Better Value Option?

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Prothena Corporation plc

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful

Equity

Bearish Sentiment

Shares of Prothena Corporation plc (PRTA) soared on Wednesday after Danish drugmaker Novo Nordisk (NVO) said that it expects to advance a drug developed by Prothena into a late-stage study for ATTR amyloidosis with cardiomyopathy.On Stocktwits, retail sentiment around Prothena jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1332/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_1_09_34_PM_png_9facc97342.webp" alt="PRTA's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1332" height="122"><figcaption>PRTA's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism for Prothena stock.<stembedurl>https://stocktwits.com/stocks271/message/623950128</stembedurl>Shares of Prothena traded 13% higher at the time of writing, while NYSE-listed shares of Novo traded 4% down.ATTR amyloidosis with cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease where misfolded transthyretin (TTR) proteins deposit in the heart muscle, leading to heart failure. Prothena-developed Coramitug is designed to deplete the abnormal protein deposits.Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. During Novo’s earnings call on Wednesday, the company said that it has successfully completed a mid-stage study of the drug and will now initiate a late-stage study during the course of 2025. The company also said that it will share detailed data from the mid-stage study at a medical conference later this year.Under the terms of the agreement between Prothena and Novo Nordisk, the former company is eligible to receive up to $1.2 billion upon achievement of clinical development and sales milestones.Prothena is also eligible to earn a clinical milestone payment when prespecified enrollment criteria are met in the late-stage clinical trial. To date, Prothena has earned $100 million from the deal.PRTA stock is down by 43% this year and by about 61% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Novo Nordisk A/S

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$8.73
Prev Close	$8.56
Open	$8.55
Dividend Yield	0.00%
50-Day Moving Average	$8.60
Beta	1.01
Avg. Volume	558,045.03
PE Ratio	-18.43

52-Week High	$11.80
52-Week Low	$7.73
Market Capitalization	$448.28M
EPS (Annual)	-$4.53
Price to Book	1.67
Revenue Per Employee	$144,537.31

Feed

News

Sentiment

Earnings

Fundamentals

Info

PRTA Fundamentals